FDA Airs Safety Concerns About Merck Insomnia Drug

Law360, New York (May 20, 2013, 7:41 PM EDT) -- The U.S. Food and Drug Administration on Monday released a clinical study of Merck & Co. Inc. insomnia drug suvorexant revealing some troubling side effects, including suicidal behavior and impaired driving performance.

In a review published two days ahead of a scheduled public meeting to discuss the drug, the FDA concluded that excessive drowsiness is the most prominent side effect and was strong enough to impact driving safety.

The agency also said the drug seems to increase the risk of suicidal thoughts and behavior, finding such...
To view the full article, register now.